Simplify Logo

Full-Time

Research Associate I/II Contract

Dmpk

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

201-500 employees

Develops drugs for muscle function improvement

Hardware
Biotechnology
Healthcare

Compensation Overview

$52 - $69Hourly

Mid

San Bruno, CA, USA

Category
Lab & Research
Life Sciences
Medical Research
Required Skills
Data Analysis
Requirements
  • Bachelor's or Master's degree in Pharmaceutical Sciences, Chemistry, Biochemistry, or a related field with 2+ years of industry experience.
  • Hands-on experience with DMPK assays, including screening, plasma protein binding, and microsomal assays are preferred but not required.
  • Proven analytical and problem-solving skills, with the ability to critically evaluate and interpret experimental data.
Responsibilities
  • Bioanalysis: plasma and tissue processing/analysis to determine the drug concentration
  • Plasma Protein Binding Studies: Conduct experiments to determine the binding affinity of compounds to plasma proteins using Sciex LC/MS-MS
  • Microsomal Assays: Perform microsomal stability studies to assess the metabolic stability and run the assay using the Sciex LC/MS-MS
  • Perform bioanalytical analysis of small molecules in plasma and the tissue using the Sciex LC/MS-MS.
  • Data Analysis and Interpretation: Analyze experimental data using appropriate software and statistical methods and provide clear and concise summaries of findings to support decision-making.
  • Documentation and Reporting: Maintain detailed records of experimental procedures, results, and observations in laboratory notebooks and electronic databases. Prepare technical reports and presentations for internal meetings and regulatory submissions.
  • Collaboration: Collaborate effectively with cross-functional teams, including medicinal chemistry, pharmacology, and toxicology, to support drug discovery and development projects.
  • Lab Maintenance: Ensure proper maintenance and organization of laboratory equipment, reagents, and supplies. Adhere to safety protocols and maintain a clean and safe working environment.

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Stage

IPO

Total Funding

$1.2B

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

0%

1 year growth

1%

2 year growth

21%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.